CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 337,917 shares, a decline of 26.4% from the March 15th total of 459,110 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily volume of 244,586 shares, the days-to-cover ratio is currently 1.4 days.

Analyst Ratings Changes

A number of analysts have weighed in on CALC shares. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Thursday, January 29th. Finally, Oppenheimer lowered their target price on CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $13.00.

CalciMedica Stock Up 1.0%

CalciMedica stock traded up $0.01 during trading hours on Friday, reaching $0.62. 9,491 shares of the company’s stock were exchanged, compared to its average volume of 1,083,076. The firm’s 50 day simple moving average is $0.64 and its 200 day simple moving average is $2.85. CalciMedica has a twelve month low of $0.46 and a twelve month high of $7.20. The firm has a market capitalization of $9.70 million, a PE ratio of -0.32 and a beta of 0.76.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter. Analysts anticipate that CalciMedica will post -2.21 EPS for the current year.

Institutional Investors Weigh In On CalciMedica

Several hedge funds and other institutional investors have recently bought and sold shares of CALC. Jane Street Group LLC bought a new position in shares of CalciMedica during the 4th quarter worth about $127,000. Cetera Investment Advisers grew its stake in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the period. PVG Asset Management Corp acquired a new stake in CalciMedica in the fourth quarter valued at approximately $302,000. Sheets Smith Investment Management bought a new stake in shares of CalciMedica during the third quarter valued at approximately $157,000. Finally, Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of CalciMedica during the third quarter worth approximately $165,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.